Keystone Nano

Webinars

Keystone Nano will host by request web-based seminars to discuss our proprietaty NanoJacket technology and how it can potentially be used for imaging, drug delivery, industrial and research chemical applications.

Sign up for Webinar - Include the approximate date you would like to participate in the additional comments and an email will be sent to you with instructions on how to participate.

Press Releases

March 5, 2009

Keystone Nano is named “Outstanding Technology Company of the Year” at the Center for Business and Industry Centre County awards gala.

July 25, 2007

Keystone Nano and Nalco Announce Joint Nanotechnology Development Venture

(Boalsburg PA) Keystone Nano, a nanotechnology development company in State College and Nalco Company (NYSE:NLC), the leading global provider of integrated water treatment and process improvement services, chemicals and equipment programs for industrial and institutional applications, announced the formation of a joint venture company, NanoSpecialties, LLC. The new company will create new products with nano-features for industrial markets.

The venture will conduct research and development of nanotechnology that allows for more precise application of various Nalco water and process treatments.
Keystone Nano has licensed two Penn State University patent applications that protect the creation of NanoJackets™, particles with a diameter of about 40 nanometers. The technology was developed through collaborative efforts between Professor James Adair’s research group in Penn State’s Materials Research Institute and Passanati Distinguished Professor Mark Kester’s research group at the Hershey Medical Center. The NanoJackets can be customized to contain specialty chemicals within an exceptionally small, effective, and safe delivery system.
These customized NanoJackets will allow:

Improved time-release of the treatment agents
Precise targeting of the treatments at the molecular level to focus the effects, and
More stable treatment agents within an engineered nanoscale package

Jeff Davidson, Keystone Nano’s CEO notes that “Combining the development and marketing strengths of Nalco with Keystone’s nanotechnology capabilities allows us to create some very exciting new products for industrial customers. We are looking forward to commercializing a range of NanoJacket applications with Nalco.”

“This effort with Keystone Nano will develop cutting-edge means to better deliver Nalco’s world-class chemistries in a variety of applications. Using nanotechnology will further improve the effectiveness of our treatment programs while reducing the amount of chemical used to achieve those results,” said Nalco Chairman and Chief Executive Officer Dr. William H. Joyce.

Keystone Nano is currently using NanoJackets to create new medical therapeutics with decreased toxicity and dosage levels. The company is also creating new research and diagnostic imaging applications featuring stable, versatile nano-imaging products.
Nalco has a long history of work in nanotechnology dating to the 1950s and the development of colloidal silicas. Recent innovations such as Core Shell® polymers, modified at the molecular level for use in wastewater treatment and as process aids in papermaking, petroleum refining, mining and food and beverage processing, continue this commitment to innovation.

Nanotechnology is the manipulation of materials at the molecular level to achieve specific results. The term derives from nanometer, a metric unit of measure equal to one billionth of a meter

About Keystone Nano
Keystone Nano is a development stage company based in State College, Pennsylvania working at the interface between nanotechnology and the life sciences. More information is available on the company at www.keystonenano.com or by calling 814-466-5080.

About Nalco
Nalco serves more than 70,000 customer locations representing a broad range of end markets. It has established a global presence with more than 11,000 employees operating in 130 countries supported by a comprehensive network of manufacturing facilities, sales offices and research centers. In 2006, Nalco achieved sales of more than $3.6 billion. For more information visit www.nalco.com.

This news release includes forward-looking statements, reflecting current analysis and expectations, based on what are believed to be reasonable assumptions. Forward-looking statements may involve known and unknown risks, uncertainties and other factors, which may cause the actual results to differ materially from those projected, stated or implied, depending on many factors, including, without limitation: ability to generate cash, ability to raise capital, ability to refinance, the result of the pursuit of strategic alternatives, ability to execute work process redesign and reduce costs, ability to execute price increases, business climate, business performance, economic and competitive uncertainties, higher manufacturing costs, reduced level of customer orders, changes in strategies, risks in developing new products and technologies, environmental and safety regulations and clean-up costs, foreign exchange rates, the impact of changes in the regulation or value of pension fund assets and liabilities, changes in generally accepted accounting principles, adverse legal and regulatory developments, including increases in the number or financial exposures of claims, lawsuits, settlements or judgments, or the inability to eliminate or reduce such financial exposures by collecting indemnity payments from insurers, the impact of increased accruals and reserves for such exposures, weather-related factors, and adverse changes in economic and political climates around the world, including terrorism and international hostilities, and other risk factors identified by the Company. Accordingly, there can be no assurance that the Company will meet future results, performance or achievements expressed or implied by such forward-looking statements. This paragraph is included to provide safe harbor for forward-looking statements, which are not generally required to be publicly revised as circumstances change, and which the Company does not intend to update.

November 2006 Yellow Cakes

Connecting the Dots Keystone Nano Targets Cancer Treatment by Judith Sen

What do you do if you have a great technology in search of a product? If you are Jeff Davidson, CEO of Keystone Nano in Boalsburg , Pennsylvania , you head off to BIO. BIO is an international biotechnology convention organized by the Biotechnology Industry Organization. “I attended the last two conventions,” said Davidson, “BIO is a great place for finding partners.” Keystone Nano has entered into partnerships with two corporate partners and is also working with three other companies interested in developing applications for the company's Molecular Dot technology...

Keystone Nano Named International Winner of The Second Annual International Nanotechnology Business Idea Competition

Company is developing Molecular Dots for Improved Disease Imaging and Drug Delivery

CLEVELAND, October 21, 2005 - Keystone Nano won the International Award of $75,000 in the second annual International and North Coast Nanotechnology Business Idea Competitions held on the campus of Case Western Reserve University. http://www.tiime.case.edu/nano/ A panel of judges featuring representatives of venture capital firms, corporations and nanotechnology researchers selected Keystone Nano as the International winner.

Keystone Nano is building its company around technology developed at Penn State University and at the Hershey Medical Center. "We'll leverage this award to speed the development of the company", said Jeff Davidson, chief executive officer of Keystone Nano. "The science is outstanding - as it allows the creation of trillions of distinct tiny drug containing Molecular Dots - now we want to build an outstanding business that uses these dots to improve human health."

"Winning the International Nanotechnology Business Idea Competition provides important validation for its technology and business team," said Mark Kester, chief medical officer for Keystone Nano. Dr. Kester is also a professor at the Penn State College of Medicine in Hershey, Pennsylvania. "We've got some momentum now and we're going to take advantage of it," Dr. Kester said.

The company has developed Molecular Dots that are 10 nanometers to 80 nanometers particles that can deliver either therapeutic drugs or imaging solutions inside a patient's body. The Molecular Dots are so tiny that they don't prompt a response from the body's immune system and can work more effectively than other internal drug delivery or imaging systems.

In the imaging area the company is working to use these MDs to more precisely image cancerous tumors earlier in the cancer development process. The goal of this early imaging is to identify cancers when they are smaller and before they have spread to other organs. Identifying cancer earlier helps improve treatment options. If Keystone Nano's imaging is successful it should result in fewer cancer deaths and more modest surgical or drug therapy interventions.

Keystone Nano's molecular dots are designed to improve the delivery of drugs that are not water soluble, or that have physical characteristics that make them difficult to deliver. These reluctant drugs can be dispatched in a miniaturized trucking force of 1,000 trillion Molecular Dots that will deliver the drugs to remote regions of the human body. The drugs delivered will improve drug therapy for patients being treated for a variety of cancers or cardiovascular diseases.

Organizers of the Nanotechnology competition include three Case Western Reserve University programs and NorTech's Nano-Network. Sponsors include ASM International, Nanofilm, Ferro Corp., Case, Forest City Enterprises, The Partnerships for Innovation Program of the National Science Foundation and the Joseph P. & Nancy F. Keithley Foundation.

Last year's top winner of the competition, QD Vision of Watertown, Mass., recently raised at least $6 million in venture capital in a venture round financed by Highland Capital Partners, North Bridge Venture Partners, and OI Ventures. Gary Wnek, co-director of TiME at Case Western Reserve University remarked "I wouldn't be surprised at all if a few of our finalists today are able to attract venture capital in the near future."